Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
U.S. Sues Teva To Block Generic Drug
by Marc S. Reisch
March 28, 2011
| A version of this story appeared in
Volume 89, Issue 13
The U.S. government has sued Teva Pharmaceutical Industries to block the sale of darunavir, a generic version of Johnson & Johnson’s Prezista protease inhibitor, used to treat HIV patients. In a filing in U.S. District Court for the District of New Jersey, the Justice Department asked FDA to withhold approval of darunavir until 2019, when a patent issued jointly to the National Institutes of Health and the University of Illinois expires. J&J’s Tibotec unit, which licenses the government patent and markets the drug, has filed a separate suit against Teva.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter